Several studies have found that dendritic cells (DCs) loaded with lysed tumor cells and IL-18 could stimulate Th1 responses against glioma antigens and markedly enhance the cytotoxic efficacy of cytotoxic T lymphocytes towards tumor cells (19,22); however, few data exist regarding the effect of MSCs modified with IL-18 gene in human tumors, and there is an urgent requirement for their effect on different types of tumors to be studied. The gene discussed is IL18; the disease is neoplasm.